Day: November 16, 2020

BRYAN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended September 30, 2020.“We made tremendous strides during the first few months of Fiscal Year 2021 in executing our strategy to transform iBio from a modestly performing contract manufacturer into a dynamic, diversified, innovative biotechnology company,” said Tom Isett, Chairman & CEO of iBio.Fiscal First Quarter and Recent Business Developments:Research & Bioprocessing Products (“RBP”)In October 2020, iBio entered into an agreement with Safi Biosolutions, Inc. (“Safi”) to evaluate iBio’s FastPharming® System for the expression of key proteins to be used in the bioprocessing of Safi blood cell...

Third Quarter 2020 Revenue Increased 40% Compared to the Second Quarter of 2020Company Expects Fourth Quarter 2020 Revenue Growth and Margin Improvement Compared to the Fourth Quarter of 2019; First Year-over-Year Increase since PandemicLOS ANGELES, Nov. 16, 2020 (GLOBE NEWSWIRE) — Barfresh Food Group, Inc. (the “Company” or “Barfresh”) (OTCQB: BRFH), a manufacturer of frozen, ready-to-blend and ready-to-drink beverages, is providing a business update in conjunction with the filing of its form 10-Q for the third quarter ended September 30, 2020.Year-to-Date Accomplishments•  Increased penetration of the education channel:Barfresh introduced its ready-to-drink beverage, Twist & Go™, into the education channel earlier this year and since its launch has expanded its education program to over 470 new school locations throughout...

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced the closing of its previously announced registered direct offering for the issuance and sale of 2,522,784 shares of its common stock, at a purchase price of $1.78375 per share. Histogen has also issued to investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 1,892,088 shares of its common stock. The offering was priced at-the-market under Nasdaq rules.H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.The warrants have an exercise price of $1.70 per share, are exercisable immediately...

Subsidiaries Take First Step Towards an IPO in ChinaPrivate Equity Round UnderwayProcess initiated to list shares of subsidiary, Tongmei, on China’s STAR MarketTwo raw material companies to be merged into TongmeiDefinitive agreements executed for initial private placement of shares of Tongmei to meet listing requirementsAXT to maintain its Nasdaq listing; its Fremont, Calif. headquarters; and its focus on global opportunitiesConference call to discuss the announcement today at 2:30 pm PT. Details included in this releaseFREMONT, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — AXT, Inc. (NasdaqGS: AXTI), a leading manufacturer of compound semiconductor substrates, today announced a strategic plan to access China’s capital markets in order to enhance its ability to support at scale the strong, expected demand for strategic compound semiconductor...

VANCOUVER, British Columbia, Nov. 16, 2020 (GLOBE NEWSWIRE) — George Sanders, President of Goldcliff Resource Corporation (“Goldcliff” or the “Company”) (GCN: TSX.V, GCFFF: OTCBB PINKS) reports that the Company has closed a Non-Brokered Private Placement Offering of 7,500,000 Units at a price of $0.10 per Unit for gross proceeds of $750,000. Each Unit will consist of one common share and one-half common share purchase warrant. Each whole Warrant will entitle the holder to purchase one additional common share at a price of $0.15 per share for a period of two years from the date of closing. Proceeds from the offering will be applied to pre drilling exploration activities at Aurora West, permitting of drilling at Aurora West, all 2021 option and land payments, due diligence expenses on additional acquisitions, and to general working...

Iceland Seafood will publish its interim consolidated financial statement for the nine months ended 30 September 2020 after closing of markets on November 18th 2020. The same day at 4.15pm, the company will host an online meeting for investors and market participants, where management will present and discuss the results.The meeting will be webcasted live in Icelandic. A link to the webcast and investor presentation will be provided before the meeting commence.  Participants to the meeting can send questions in writing prior and during the meeting to the email investors@icelandseafood.com.

TULSA, Okla., Nov. 16, 2020 (GLOBE NEWSWIRE) — Educational Development Corporation (“EDC”, or the “Company”) (NASDAQ: EDUC) (http://www.edcpub.com) reports that the Company will participate in the virtual Southwest IDEAS Investor Conference on November 19th, 2020. EDC’s presentation will be webcasted and is scheduled to be available at 7:00 am CST on November 18th. The presentation can be accessed through the Southwest IDEAS conference portal for registered participants, on the IDEAS conference website: www.IDEASconferences.com, or on the Company’s website: http://www.edcpub.com/investmentconference following the conference. The presentation includes guidance on net revenues and earnings per share for the fiscal year ending February 28, 2021.About IDEAS Investor ConferencesThe mission of the IDEAS Conferences is to provide...

Anaheim, CA, Nov. 16, 2020 (GLOBE NEWSWIRE) — LiveWire Ergogenics Inc. (OTC: LVVV), a company focused on acquiring and managing special purpose real estate properties conducive to producing high-quality, organically-grown and handcrafted cannabis products for medicinal and recreational use in California, today announced its financial results for Q3 ending September 30, 2020.Bill Hodson, CEO of LiveWire Ergogenics states, “We are nearing the end of a very intense year in so many ways, from a paralyzing pandemic to a very turbulent election year, but we feel that the pending changes in Washington will result in the advancement towards federal legalization of cannabis. In our immediate environment it has been a year of managing the complex approval process for legal and environmental compliance prior to operation on our Estrella Ranch...

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 16 nov. 2020 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq : MRUS), une société d’oncologie au stade clinique qui développe des anticorps multispécifiques de pleine longueur innovants (Biclonics® et Triclonics™), a annoncé aujourd’hui que Bill Lundberg, M.D., président-directeur général, participera à une discussion informelle lors de la Jefferies Virtual London Healthcare Conference le mardi 17 novembre 2020 à 14 h 40 GMT/9 h 40 HNE.Une diffusion en direct de la présentation sera disponible sur la page consacrée aux investisseurs du site Web de la Société, http://www.merus.nl. Une présentation archivée sera disponible sur le site Web de Merus pendant une durée limitée.À propos de MerusMerus est une entreprise d’oncologie de stade clinique qui développe des traitements innovants...

UTRECHT, Niederlande, und CAMBRIDGE, Mass., USA, Nov. 16, 2020 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische volllange Antikörper (Biclonics® und Triclonics™) entwickelt, hat heute bekannt gegeben, dass Bill Lundberg, M.D., President und Chief Executive Officer, am Dienstag, den 17. November 2020, um 14:40 Uhr GMT/9:40 ET an einem Kamingespräch auf der Jefferies Virtual London Healthcare Conference teilnehmen wird.Ein Live-Webcast der Präsentation wird auf der Unternehmenswebsite in der Rubrik Investoren zur Verfügung gestellt: http://www.merus.nl. Eine Aufzeichnung der Präsentation wird ebenfalls für einen begrenzten Zeitraum auf der Website von Merus verfügbar sein.Über MerusMerus ist ein Unternehmen im Bereich der klinischen Onkologie, das...